SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies...

Owlstone Medical (or the “Company”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, has announced the publication of a peer-reviewed study in Nature Scientific Reports. The paper investigates the performance of filters embedded in face masks for supporting the detection of SARS-CoV-2 as an alternative to nasopharyngeal swabs (NPS)...

Designed and manufactured in the UK, Σ–MM™ solution rapidly kills all microorganisms, including bacteria, mycobacteria and viruses, rendering specimens safe for transport, whilst preserving and stabilizing RNA/DNA for accurate molecular analysis across diagnostic platforms. The Σ–MM™ device is a highly effective single step collection....

The race is on in the diagnostics industry to develop a device that instantly detects coronavirus for use in large public spaces and airports, according to one of the UK’s top medical technology recruiters. Ivor Campbell, chief executive of Snedden Campbell, said the biggest companies are chasing the ‘holy grail’ of a rapid-test, biosensing device – similar to that used to test blood sugar levels in diabetic patients – that will identify whether a patient has Covid within a matter of seconds...

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, announced the launch of the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements. The Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) is a single molecular test designed for clinical diagnostic labs that conduct COVID-19 testing...

FreeLIMS, a cloud-based COVID-19 LIMS solution, enables laboratories to increase testing throughput and meet the unprecedented demand for COVID-19 testing and research. FreeLIMS enables COVID-19 testing laboratories to securely manage samples and test results, protect Personally Identifiable Information (PII) of patients, assure the accuracy of test results, and generate custom test reports with ease...

VectorBuilder – a global leader in vector design, optimization and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable viral vector production. VectorBuilder’s manufacturing center in Guangzhou, China, will work with Univercells Technologies to develop and optimize platform processes for the production of custom viral vectors for cell and gene therapies, as well as vaccine applications....

Avacta Group plc, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Calibre Scientific Inc. (“Calibre”), a global provider of life science products, for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK and European Economic Area (EEA)...

As the demand for rapid SARS-CoV-2 testing continues to grow, so does the need for accurate, reliable and fast results. Gilson’s new COVID-19 Testing Fluid News Brochure highlights their range of world-renown and trusted manual and automated lab solutions that can easily integrate into your qPCR and RT-Lamp testing workflows. When protection, speed of analysis, reliability and traceability are paramount, Gilson’s range of lab equipment and instruments delivers verifiable data and complete confidence in results...

The CEO of a British technology training firm and tech think tank has warned of a looming crisis facing UK laboratories – in particular those at the forefront of Covid-19 testing – due to a massive shortage of qualified and skilled lab technicians. Andy Lord, CEO of Manchester head-quartered Credersi, a tech talent training incubator and think tank producing the data scientists, lab technicians and software specialists of tomorrow, believes the skills shortage could severely impact Covid testing laboratories...

Porvair Sciences has further expanded its range of high-performance microplate products for SARS-CoV-2 nucleic acid purification. The new KF deep well plate and tip comb plate combo are specifically designed to enhance the performance and productivity of the market-leading Thermo Scientific™ KingFisher™ range of nucleic acid purification systems....

Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem. The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity...

AMSBIO invite the global research community to the 2021 annual meeting of the ISSCR, the leading professional organization of stem cell scientists, to discover how iPSCs and organoids can be used in COVID-19 drug discovery research. At this virtual meeting - Dr. Kazuo Takayama from the renowned Center for iPS Cell Research and application (CiRA) at Kyoto University will be giving a unique insight into his recent pioneering research...

The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards. The award recognises the Company’s outstanding contribution to the fight against COVID-19....

As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active substance ProcCluster(R) reduces the viral load by 90% and acts against infection-related inflammatory processes without developing a resistance. It is already used on humans...

Avacta Group plc the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer^® and pre|CISION™ platforms, is pleased to announce that the MHRA has confirmed registration of Avacta’s AffiDX^® SARS-CoV-2 antigen lateral flow test allowing the Company to place the product on the market in the UK for professional use...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has announced that it has entered into an agreement with Thermo Fisher Scientific for fill/finish sterile manufacturing services and supply packaging for Moderna’s COVID-19 vaccine. Under the terms of the agreement, Thermo Fisher’s commercial manufacturing site in Greenville, North Carolina will be used for aseptic fill/finish, labeling and packaging...

The very high use of antibiotics in patients hospitalised with COVID-19 is often not necessary, and risks worsening global antimicrobial resistance. New research led by the University of Glasgow as part of the ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) WHO Clinical Characterisation Protocol UK (CCP-UK), found that antibiotic use was very high in hospitalised COVID-19 patients in the UK during the first wave despite confirmed bacterial infection being uncommon....

Malvern Panalytical was delighted to welcome His Royal Highness The Earl of Wessex to its Malvern, Worcestershire, headquarters. Malvern Panalytical was selected for the Royal visit, amongst a small number of other Worcestershire businesses, primarily because of its scientific and technical contribution to the development of medicines and vaccines to treat and prevent COVID-19...